TALWIN 50 Drug Patent Profile
✉ Email this page to a colleague
Which patents cover Talwin 50, and what generic alternatives are available?
Talwin 50 is a drug marketed by Sanofi Aventis Us and is included in one NDA.
The generic ingredient in TALWIN 50 is pentazocine hydrochloride. There are five drug master file entries for this compound. Additional details are available on the pentazocine hydrochloride profile page.
Summary for TALWIN 50
| US Patents: | 0 |
| Applicants: | 1 |
| NDAs: | 1 |
| Raw Ingredient (Bulk) Api Vendors: | 6 |
| Clinical Trials: | 1 |
| Patent Applications: | 962 |
| Formulation / Manufacturing: | see details |
| DailyMed Link: | TALWIN 50 at DailyMed |
Recent Clinical Trials for TALWIN 50
Identify potential brand extensions & 505(b)(2) entrants
| Sponsor | Phase |
|---|---|
| Mclean Hospital | Phase 2 |
| Stanley Medical Research Institute | Phase 2 |
Anatomical Therapeutic Chemical (ATC) Classes for TALWIN 50
US Patents and Regulatory Information for TALWIN 50
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Exclusivity Expiration |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Sanofi Aventis Us | TALWIN 50 | pentazocine hydrochloride | TABLET;ORAL | 016732-001 | Approved Prior to Jan 1, 1982 | DISCN | No | No | ⤷ Try a Trial | ⤷ Try a Trial | ⤷ Try a Trial | ||||
| >Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Exclusivity Expiration |
